医药生物行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002365 | 永安药业 | -4.28 | 40.91 | -13714.20 | | 002693 | 双成药业 | -9.97 | 18.88 | -13065.36 | | 600196 | 复星医药 | -0.25 | 0.82 | -8302.56 | | 003020 | 立方制药 | -10.00 | 17.63 | -8292.64 | | 603205 | 健尔康 | -7.02 | 46.99 | -7465.10 | | 002422 | 科伦药业 | -6.60 | 2.41 | -7319.24 | | 002044 | 美年健康 | -1.92 | 3.40 | -7167.05 | | 688578 | 艾力斯 | -3.48 | 1.26 | -6411.86 | | 600216 | 浙江医药 | -1.30 | 3.42 | -6123.73 | | 300401 | 花园生物 | -4 ...

永安药业今日下跌4.28%，全天换手率40.91%，成交额13.14亿元，振幅14.94%。龙虎榜数据显示，机构 净买入1385.74万元，营业部席位合计净卖出6223.97万元。 深交所公开信息显示，当日该股因日换手率达40.91%上榜，机构专用席位净买入1385.74万元。 资金流向方面，今日该股主力资金净流出1.37亿元，其中，特大单净流出6671.44万元，大单资金净流出 7042.76万元。近5日主力资金净流入1.09亿元。（数据宝） 永安药业4月25日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 联储证券股份有限公司浙江分公司 | 2723.77 | 0.00 | | 买二 | 中信证券股份有限公司上海溧阳路证券营业部 | 2318.44 | 16.82 | | 买三 | 开源证券股份有限公司西安太华路证券营业部 | 2045.72 | 1917.46 | | 买四 | 机构专用 | 2025.31 | 639.57 | | 买五 | 国投证券股份有限公司西安朱雀大街证券营业部 | 1 ...

New Stock Listings - The new stock "Zhongjie Automobile" (code: 301560) is listed at an issuance price of 16.50[1] Rights Issues and Offers - Cash option for "AVIC Capital" (code: 600705) is available from April 23 to April 25, 2025[1] - Tender offer for "ST Xinchao" (code: 600777) is open from April 23 to May 22, 2025[1] - "ST Puli" (code: 300630) will enter the delisting arrangement period starting April 28, 2025[1] Market Alerts - "Guoguang Chain" (code: 605188) has reported severe abnormal fluctuations[1] - "Dongfang Tong" (code: 300379) also reported severe abnormal fluctuations[1] Other Announcements - "Huili B" (code: 900939) has a recent announcement linked to its trading activities[1] - "Zhejiang Rongtai" (code: 603119) has a recent announcement linked to its trading activities[1] - "ST Jiuyou" (code: 600462) has a recent announcement linked to its trading activities[1]

Core Viewpoint - The vitamin sector in the A-share market experienced a strong surge, primarily driven by a significant increase in the price of vitamin D3, with various companies showing substantial stock price gains [1][3][9]. Price Movements - The price of feed-grade vitamin D3 was raised to 600 RMB per kilogram domestically, while the export price soared to 75 USD per kilogram (approximately 540 RMB per kilogram), marking a new high for 2023 [3]. - Major companies in the vitamin sector, such as Erkang Pharmaceutical, Brother Technology, and Yong'an Pharmaceutical, saw their stock prices hit the daily limit up, with Erkang Pharmaceutical's stock price increasing by 20% to 3.12 RMB [1][2]. Supply Chain Dynamics - The collective halt in price reporting by major domestic manufacturers and urgent inventory shortages in the European market have contributed to the rising prices of vitamin D3 [4]. - The explosion at BASF's factory in Ludwigshafen, Germany, has led to a significant supply shortage of vitamins A and E, further driving up global vitamin prices [5][6]. Company Performance - Erkang Pharmaceutical reported a total revenue of 354 million RMB for Q1 2025, a year-on-year increase of 28.19%, with net profit soaring by 868.91% to 28.11 million RMB [9]. - Brother Technology projected a net profit of 18 to 23 million RMB for Q1 2025, marking a turnaround from losses, attributed to rising sales prices of certain vitamin products [9]. - New Hec's expected net profit for Q1 2025 is projected to be between 1.8 billion to 1.9 billion RMB, reflecting a year-on-year growth of 107% to 118% [9]. Market Outlook - Analysts expect that the vitamin prices will remain high in the short term due to ongoing supply constraints and the concentration of production in China [7][10]. - The domestic share of the vitamin market is anticipated to continue increasing, with projections indicating that by 2024, China's production will account for approximately 86% of the global market [10].

近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.04.23 | 9.97 | 6.97 | 9161.66 | | 2025.04.22 | 3.13 | 18.75 | 1954.66 | | 2025.04.21 | 9.98 | 16.24 | 8100.36 | | 2025.04.18 | -4.85 | 8.82 | -3046.83 | | 2025.04.17 | 2.05 | 9.28 | 861.64 | | 2025.04.16 | -0.85 | 9.08 | -565.13 | | 2025.04.15 | -4.87 | 14.32 | -1656.52 | | 2025.04.14 | -2.86 | 17.79 | -2185.20 | | 2025.04.11 | -2.87 | 24.53 | -4921.80 | | 2025.04.10 | 6.10 | 27.61 | 4910.80 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 永安药 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-20 潜江永安药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 4 月 21 日、2025 年 4 月 22 日、2025 年 4 月 23 日连续 3 个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳 证券交易所的有关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人 就相关事项进行了核实，现就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 （二）经核查，公司未发现近期公共媒体报道了可能或者已经对公司股票交易 价格产生较大影响的未公开重大信息。 （三）经核查，公司近期经营情况正常，内外部经营环境未发生重大变化。 （四）经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而 未披露的重大事 ...

潜江永安药业股份有限公司 证券代码：002365 证券简称：永安药业 公告编号：2025-19 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2024 年 4 月 29 日、2024 年 6 月 21 日分别召开了第六届董事会第二十一次会议及 2023 年年度股东大会， 审议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计 使用最高额度不超过（含）人民币 7 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东大会审议通过之日起不超过 12 个月，并授权公司管 理层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有 关情况公告如下： 一、理财产品的主要情况 （一）2025 年 4 月 22 日，公司出资 3000 万元，向广发证券股份有限公司 （以下简称"广发证券"）购买理财产品，具体情况如下： 1、产品名称：粤财信托·广粤双盈 2 号集合资金信托计划 2、产品代码：YCOG8A 3、产品主要投资范围：本信托计划成立后，信托资金投资于信托业 ...

Group 1: Financial Performance and Market Strategy - The company is focusing on stabilizing existing European and American clients while exploring emerging markets to mitigate risks from international market fluctuations and exchange rate volatility [3]. - The company plans to disclose its Q1 2025 report on April 29, 2025, and is closely monitoring the impact of increasing tariffs on its U.S. market operations [3]. - Recent revenue declines are attributed to the termination of partnerships and a downturn in the construction industry, prompting the company to develop new products to stabilize revenue growth [5]. Group 2: Competitive Position and Industry Outlook - The company maintains a leading position in the taurine industry and is committed to enhancing its core competitiveness through market expansion, technological optimization, and cost reduction [3]. - The taurine market is expected to grow steadily due to its unique functions and increasing consumer health awareness, with applications expanding in food, beverages, and health products [8]. - The company is actively seeking diversification opportunities, including new product developments in creatine and phenoxyethanol [5]. Group 3: Legal and Regulatory Matters - The company is involved in a patent lawsuit in the U.S., with a favorable ruling received in February 2024, although the opposing party has appealed [6][7]. - The company is monitoring the bankruptcy proceedings of the opposing party in the patent case, which has temporarily halted the appeal process [7]. Group 4: Future Development Plans - The company aims to enhance energy efficiency and environmental sustainability while advancing its taurine business over the next five years, with a focus on carbon neutrality and smart technology [11]. - The expansion project for taurine production is nearing completion and will soon enter the acceptance phase [13]. - The sub-brand "Yijianeng" is making progress in both online and offline channels, with sales increasing through major e-commerce platforms and pharmacy chains [12].

Investment Rating - The report maintains a "Hold" rating for the healthcare sector [8] Core Viewpoints - The pharmaceutical sector slightly underperformed the CSI 300 index, with a decline of 5.61% from April 7 to April 11, 2025, ranking 22nd among 31 sectors [3][13] - Year-to-date, the pharmaceutical index has decreased by 1.10%, outperforming the CSI 300 index by 3.59 percentage points, ranking 13th among 31 sectors [15] - As of April 11, 2025, the valuation of the pharmaceutical sector stands at 25.91 times (TTM overall method, excluding negative values), with a premium of 141.73% compared to the CSI 300 index [18] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 7 to April 11, 2025, shows a decline of 5.61%, underperforming the CSI 300 index by 2.74 percentage points [3][13] - The valuation level of the pharmaceutical sector is reported at 25.91 times, with a significant premium over the CSI 300 index [18] - Top-performing stocks include Yirui Technology (+20.54%), Yipinhong (+17.03%), and Yong'an Pharmaceutical (+13.93%) [19][20] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, along with 12 other departments, issued the "Special Action Plan for Promoting Healthy Consumption" to enhance the quality of health goods and services [5][22] 3. Important Company Announcements - Haizike reported a revenue of 3.721 billion yuan for 2024, a year-on-year increase of 10.92%, with a net profit of 395 million yuan, up 34.00% [23] - Kexing Pharmaceutical announced a revenue of 1.407 billion yuan for 2024, with a net profit of 31 million yuan, marking a return to profitability [23] 4. Industry Perspectives - The report discusses the impact of the ongoing trade war, noting that while pharmaceuticals were initially included in tariff discussions, they were later excluded from the "reciprocal tariffs" announced by the U.S. government [6][25] - The report highlights that increased tariffs on imports from the U.S. could benefit domestic substitutes in the blood products, high-end medical devices, and innovative drug sectors [6][26]

证券代码：002365 证券简称：永安药业 公告编号：2025-18 登录新浪财经APP 搜索【信披】查看更多考评等级 4、会议问题征集：投资者可于2025年04月16日前访问网址 https://eseb.cn/1nnBDGmqsoM或使用微信扫 描下方小程序码进行会前提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 ■ 潜江永安药业股份有限公司（以下简称"公司"）已于2025年4月10日在中国证监会指定信息披露媒体巨 潮资讯网 http://www.cninfo.com.cn 上披露《2024年年度报告》及《2024年年度报告摘要》。为了让广大 投资者进一步了解公司2024年度经营业绩等情况，公司决定于2025年04月16日（星期三）15:00-17:00以 网络文字互动方式在"价值在线"（www.ir-online.cn）举办2024年度业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。欢迎广大投资者积极参与！ 一、说明会召开的时间、地点和方式 潜江永安药业股份有限公司 关于举办2024年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真 ...